Insights - Orexigen Therapeutics’ (OREX) obesity drug Contrave did not increase the risk of cardiovascular events (heart attack, etc.) past a specified threshold in an interim look … Continue Reading
PremiumLong Ideas - Last December, we called Orexigen (OREX) the obesity stock to own in 2013. Thus far, we’ve been spot on. Arena (ARNA) and Vivus (VVUS) have … Continue Reading
Read nowLong Ideas - Since late last year when Orexigen (OREX) revealed that its cardiovascular outcomes trial, the LIGHT study, was enrolling faster than anticipated and that the FDA … Continue Reading
Read nowLong Ideas - Orexigen Therapeutics (OREX) will be the last of three leading weight-loss drug developers to enter the large potential market for new obesity treatments, and biotech … Continue Reading
Read nowLong Ideas - Orexigen Therapeutics (NASDAQ:OREX) will be releasing its third quarter earnings report after the market’s close Wednesday night, and with all of the hoopla surrounding obesity … Continue Reading
Read now- This morning, Orexigen (NASDAQ:OREX) stated that the LIGHT Study, a trial requested by the FDA to evaluate cardiovascular risk for the company’s obesity treatment candidate, … Continue Reading
Read now
